These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9819884)

  • 21. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
    Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
    Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Spasticity: therapy of increased reflexes or movement disorder?].
    Dietz V
    Nervenarzt; 1990 Oct; 61(10):581-6. PubMed ID: 2274090
    [No Abstract]   [Full Text] [Related]  

  • 23. [Spastic syndrome and main directions of its treatment].
    Damulin IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(12):4-9. PubMed ID: 14763249
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis.
    Knutsson E; Mårtensson A; Gransberg L
    J Neurol Sci; 1982 Feb; 53(2):187-204. PubMed ID: 7035623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study of a new myorelaxant in neurological affections (author's transl)].
    Chantraine A; Van Ouwenaller C
    J Belge Med Phys Rehabil; 1981; 4(1):5-14. PubMed ID: 7309686
    [No Abstract]   [Full Text] [Related]  

  • 26. [The use of sirdalud in cerebral palsy in children].
    Brin IL; Kurenkov AL; Gotlib VIa
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(10):30-3. PubMed ID: 10536809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke.
    Stamenova P; Koytchev R; Kuhn K; Hansen C; Horvath F; Ramm S; Pongratz D
    Eur J Neurol; 2005 Jun; 12(6):453-61. PubMed ID: 15885050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of tizanidine in the treatment of spasticity.
    Neurology; 1994 Nov; 44(11 Suppl 9):S1-80. PubMed ID: 7970005
    [No Abstract]   [Full Text] [Related]  

  • 29. [A randomized, double blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke].
    Stamenova P; Koytchev R; Kuhn K; Hanasen C; Horvath F; Ramm S; Pongratz D
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(1):34-42. PubMed ID: 16457132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Current data on bipolar disorders, epilepsy and spasticity. 4. Neuro-Forum, Dresden].
    Fortschr Neurol Psychiatr; 1999 May; 67(5 Suppl Aktuelles):1-12. PubMed ID: 10368778
    [No Abstract]   [Full Text] [Related]  

  • 31. Spasticity: a review.
    Young RR
    Neurology; 1994 Nov; 44(11 Suppl 9):S12-20. PubMed ID: 7970006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Sirdalud in the practice of the pediatric neurologist].
    Shumilina AP; Guzeva VI; Skoromets AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(10):45-6. PubMed ID: 9424348
    [No Abstract]   [Full Text] [Related]  

  • 33. Spasticity: revisiting the role and the individual value of several pharmacological treatments.
    Lapeyre E; Kuks JB; Meijler WJ
    NeuroRehabilitation; 2010; 27(2):193-200. PubMed ID: 20871149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cortical activity modulation by botulinum toxin type A in patients with post-stroke arm spasticity: real and imagined hand movement.
    Veverka T; Hluštík P; Hok P; Otruba P; Tüdös Z; Zapletalová J; Krobot A; Kaňovský P
    J Neurol Sci; 2014 Nov; 346(1-2):276-83. PubMed ID: 25255982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens.
    Slawek J; Bogucki A; Reclawowicz D
    Neurol Sci; 2005 Apr; 26(1):32-9. PubMed ID: 15877185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new skeletal muscle relaxant (DS 103-282) compared to diazepam in the treatment of muscle spasm of local origin.
    Hennies OL
    J Int Med Res; 1981; 9(1):62-8. PubMed ID: 6451461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the myotonolytic activity of tizanidine, eperisone and afloqualone in mouse and rabbit.
    Coward DM; White TG
    J Int Med Res; 1989; 17(4):358-62. PubMed ID: 2792555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
    Groves L; Shellenberger MK; Davis CS
    Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantification of the effects of muscle relaxant drugs in man by tonic stretch reflex.
    Meyer M; Adorjáni C
    Adv Neurol; 1983; 39():997-1011. PubMed ID: 6660131
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.